Sector News

Pfizer looks to rebuild abandoned vaccines biz in China

November 2, 2016
Life sciences

More than a year after pulling its vaccines out of one of the world’s most challenging but lucrative drug markets, Pfizer has moved back into China with a nod for big-selling Prevenar 13.

With that green light in hand for its pneumococcal disease blocker, a key contributor to Pfizer’s overall business, the company is working on a launch timeline, a spokesperson told FiercePharma.

Pfizer didn’t indicate what level of sales the new market could bring, but even a small boost could help the shot, sold in the U.S. as Prevnar 13. After boasting double-digit growth for some time, the shot has struggled in recent quarters; for Q3, sales fell 3% to $1.54 billion. In September, analysts with EvaluatePharma predicted Prevnar 13 would slip 1% yearly through 2022.

The new approval in China covers Prevenar 13 in children aged six weeks to 15 months. Approximately 30,000 children in that age range die in China from pneumococcal diseases each year.

The Chinese government nod is a turnabout for Pfizer in that vaccines market, which the drug giant decided to abandon last year. Pfizer moved to pull its vaccines from the country after the import license for Prevenar 13’s predecessor wasn’t renewed. That decision affected 200 employees in vaccine sales, according to reports at the time.

Now, Pfizer will be staffing back up for the new launch. A Pfizer spokesperson didn’t specify staffing numbers, but said the company looks “forward to building a strong vaccines business in China, and we aim to attract the most qualified talent.”

Prevenar 13’s approval in China could serve as a much-needed boost for a franchise that has struggled in recent quarters after posting enormous growth last year. The shot brought $6.24 billion to Pfizer’s top line in 2015.

In 2014, a key CDC committee in the U.S. recommended the vaccine for adults over 65, creating an opportunity for a $2 billion sales boost. But because of a “high initial capture rate,” Pfizer now says the franchise is suffering from an “expected decline.”

By Eric Sagonowsky

Source: Fierce Pharma

comments closed

Related News

February 4, 2023

MedTrace receives U.S. patent for diagnosing the human heart

Life sciences

The U.S. Patent and Trademark Office issued a patent to MedTrace for their method of diagnosing the human heart via 15O-water PET. The patented method is the foundation of the company’s software aQuant, currently under development. Hendrik “Hans” Harms, PhD and Senior Scientist at MedTrace, and Jens Soerensen, Professor and Clinical Advisor to MedTrace, are the originators of the method.

February 4, 2023

Roche taps insider Teresa Graham for top pharma job as setbacks prompt M&A questions

Life sciences

Teresa Graham, currently head of global product strategy for Roche pharma, will become the division’s new CEO next month, Roche said Thursday. Simultaneously, Roche is elevating Levi Garraway, chief medical officer, to the executive committee.

February 4, 2023

J&J’s pharma group quietly works through global overhaul, with layoffs expected to reach multiple countries

Life sciences

Fierce Pharma has obtained internal documents and video of a town hall meeting conducted this week describing what J&J called a “comprehensive review” of its portfolio. Moving forward, J&J plans to operate its vaccines and infectious diseases outfits as one group, the executives explained.

How can we help you?

We're easy to reach